Supplementary Material

Survey Results 2013
38 of 56 centres responded.
1)
How does your centre currently deliver anal cancer chemoradiation?  37% delivering IMRT on all or selected patients.  63% delivering ACT2 style treatment entirely. We are just starting to use IMRT but at the moment lack both capacity and expertise
4)
Would your centre be prepared to implement IMRT using guidelines developed by the colorectal CSG?  100% were happy to implement using national guidance.
5)
How long would it take for your centre to treat the first patient with the new technique? Predicted time to implement IMRT 6) Would your centre be prepared to prospectively collect data at two timepoints (end of chemo/XRT and 3 months post XRT/chemo) in a minimum of five consecutive patients within a UK wide audit?  100% keen to participate in an UK audit of anal cancer.
7)
Is PET/CT used in the workup for your anal cancer patients? We are in process of developing IMRT for our anal cancers  We have treated 55 pts with IMRT so far.  At our centre, we would be very keen to IMRT for treatment of anal canal cancer, in addition to the sites where it is currently used. Unfortunately due to current pressures within the department, particularly related to physics support, it would be difficult to introduce treatment right away, but it would be desirable to do so in the near future. Involvement in a national trial would be an excellent way to introduce new practice, and we would be very keen to be involved.

We would be very keen to participate  We are integrating IMRT volumes into our work instructions currently and hope to transition to IMRT based delivery of treatment in the next 3 months  Our results are excellent. In my view we need to lower the acute and late toxicity by changing the chemotherapy schedule.  Happy to support IMRT for this site which we were thinking of starting soon!  Very good results with current protocol with only one salvage APR needed in 5 years.  Time taken for IMRT is not included in our job plans. 
